| Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease. | |
| | |
MedLine Citation:
|
PMID: 6421866 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Thyroidal suppressibility by exogenous T3 in terms of both radioiodine uptake (RAIU) and serum T4 was evaluated in 115 hyperthyroid patients treated with methimazole for 2 yr and followed for an additional 2 yr to study the rate of recurrence. Various other serum parameters including serum thyroglobulin concentrations, thyroid autoantibody, and TSH receptor antibody titers, and thyroidal responses to TRH-induced TSH elevation were also determined. After 2 yr of methimazole therapy, thyroidal RAIU was not suppressible (RAIU less than 12%/4 h was defined as suppressible) in 50 of 115 patients (group I). Of 65 patients with suppressible thyroid RAIU, serum T4 was significantly reduced (less than 60% of pre-T3 level) by T3 administration in only 43 patients (group III) but not in the remainder (group II). Antithyroid drug therapy was discontinued in the group II and III patients, and 7 of the patients had recurrence of hyperthyroidism within 2 yr of follow-up. All of them were from group II. The thyroidal response to TSH was greater in group III patients than in group II patients. During antithyroid drug therapy, decrease of microsomal antibody titer was more likely to occur in group III patients than in those of group II. Serum thyroglobulin concentrations were uniformly normal in treated patients irrespective of T3 suppressibility. TSH receptor antibody was positive in all 13 untreated patients with Graves' disease but was negative in treated patients regardless of their T3 suppressibility. Measurement of both thyroidal RAIU and serum T4 after administration of T3 improves the reliability of T3-suppression testing as a predictor of the remission of Graves' disease. |
| | |
Authors:
|
T Yamada; Y Koizumi; A Sato; K Hashizume; T Aizawa; N Takasu; H Nagata |
Related Documents
:
|
10397076 - Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical cr... 708096 - Neurological abnormalities in patients treated for hypothyroidism from early life. 9855346 - Optimal management of amiodarone therapy: efficacy and side effects. 7488816 - Frequency, clinical and laboratory features of thyroiditis in girls with turner's syndr... 18831656 - Long-term outcomes and prognostic factors in pediatric patients with severe traumatic b... 3167916 - Prevalence of mitral valve prolapse in chronic lymphocytic thyroiditis and nongoitrous ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 58 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 1984 Apr |
Date Detail:
|
Created Date: 1984-04-20 Completed Date: 1984-04-20 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 676-80 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Autoantibodies / metabolism Child Evaluation Studies as Topic Female Graves Disease / drug therapy* Humans Iodine Radioisotopes / diagnostic use Male Methimazole / therapeutic use* Middle Aged Prognosis Thyroglobulin / metabolism Thyroid Function Tests / methods Thyroid Gland / immunology, metabolism Thyrotropin / secretion Thyrotropin-Releasing Hormone / diagnostic use Thyroxine / blood Triiodothyronine / diagnostic use* |
| Chemical | |
Reg. No./Substance:
|
0/Autoantibodies; 0/Iodine Radioisotopes; 24305-27-9/Thyrotropin-Releasing Hormone; 60-56-0/Methimazole; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin; 9010-34-8/Thyroglobulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A competitive ligand binding assay for measurement of thyroid hormone-binding inhibitor in serum and...
Next Document: Histamine-induced paradoxical growth hormone response to thyrotropin-releasing hormone in normal men...